Abstract
The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have